Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

BioPharma Terug naar discussie overzicht

Insmed, in de gaten houden

20.047 Posts
Pagina: «« 1 ... 845 846 847 848 849 ... 1003 »» | Laatste | Omlaag ↓
  1. [verwijderd] 13 juni 2006 14:13

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Press Release Source: Insmed Incorporated

    Court Dismisses Baseless Unfair Business Practices Lawsuit That Was Brought Against Insmed
    Tuesday June 13, 8:04 am ET

    RICHMOND, Va.--(BUSINESS WIRE)--June 13, 2006--Insmed Incorporated (Nasdaq:INSM - News): On June 9, 2006, the United States District Court for the Northern District of California (Judge Saundra Brown Armstrong) granted Insmed's Motion to Dismiss the Complaint filed by Tercica, Inc. in the case Tercica, Inc. vs. Insmed Incorporated. The Complaint, filed and amended in December 2005, alleged violations of the California Business and Professions Code and the federal Lanham Act for allegedly false and misleading statements made by Insmed. In dismissing the Complaint, the Court ruled, among other things, that Tercica had not met its burden of establishing that the alleged statements made by Insmed constitute "false advertising", or that the Court had jurisdiction over Insmed in this case and that the venue was proper. Further, by dismissing Tercica's complaint without leave to amend, the Court recognized that the deficiencies in Tercica's lawsuit cannot be cured by filing another lawsuit against Insmed in the United States District Court for the Northern District of California. Insmed previously notified Tercica that Insmed would seek fees and costs related to Tercica's baseless lawsuit. Given the Court's ruling, Insmed will pursue this option.


    "We are pleased that the Court ruled that Tercica's complaint was without merit and upheld Insmed's right to inform the investment community about our product development activities related to IPLEX(TM) without violating the Lanham Act," stated Geoffrey Allan, Insmed's Chief Executive Officer. "In line with Tercica's continuing preference to litigate, Tercica has indicated they have filed a new lawsuit against Insmed in the Virginia courts that is similar to the lawsuit dismissed in California. As with the California case, Insmed will vigorously defend its position and right to inform the investment community about product development activities."
  2. [verwijderd] 13 juni 2006 14:13

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Press Release Source: Insmed Incorporated

    Court Dismisses Baseless Unfair Business Practices Lawsuit That Was Brought Against Insmed
    Tuesday June 13, 8:04 am ET

    RICHMOND, Va.--(BUSINESS WIRE)--June 13, 2006--Insmed Incorporated (Nasdaq:INSM - News): On June 9, 2006, the United States District Court for the Northern District of California (Judge Saundra Brown Armstrong) granted Insmed's Motion to Dismiss the Complaint filed by Tercica, Inc. in the case Tercica, Inc. vs. Insmed Incorporated. The Complaint, filed and amended in December 2005, alleged violations of the California Business and Professions Code and the federal Lanham Act for allegedly false and misleading statements made by Insmed. In dismissing the Complaint, the Court ruled, among other things, that Tercica had not met its burden of establishing that the alleged statements made by Insmed constitute "false advertising", or that the Court had jurisdiction over Insmed in this case and that the venue was proper. Further, by dismissing Tercica's complaint without leave to amend, the Court recognized that the deficiencies in Tercica's lawsuit cannot be cured by filing another lawsuit against Insmed in the United States District Court for the Northern District of California. Insmed previously notified Tercica that Insmed would seek fees and costs related to Tercica's baseless lawsuit. Given the Court's ruling, Insmed will pursue this option.
    ADVERTISEMENT




    "We are pleased that the Court ruled that Tercica's complaint was without merit and upheld Insmed's right to inform the investment community about our product development activities related to IPLEX(TM) without violating the Lanham Act," stated Geoffrey Allan, Insmed's Chief Executive Officer. "In line with Tercica's continuing preference to litigate, Tercica has indicated they have filed a new lawsuit against Insmed in the Virginia courts that is similar to the lawsuit dismissed in California. As with the California case, Insmed will vigorously defend its position and right to inform the investment community about product development activities."

    About Insmed

    Insmed is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit www.insmed.com.

    Forward Looking Statements

    Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for the purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding the pending litigation and or future ability to conduct our business as now conducted and as it is currently proposed to be conducted. Such forward-looking statements are subject to numerous risks and uncertainties, including but not limited to the uncertainty of the outcome of any litigation with Tercica. We can give no assurances that we would be successful in any litigation or that such litigation would not have a material adverse effect on our business, financial condition and results of operation. Furthermore, we may not be able to afford the expense of defending against such a claim. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release. For further information with respect to factors that could cause actual results to differ from expectations, reference is made to reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended.
  4. [verwijderd] 13 juni 2006 14:15

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Rieltijm schreef:

    Bijna gelijkertijd rac, beter 2x dan niet.....

    Ries
    zekers.koers reageert ook meteen.

    Pre-Market (RT-ECN): 1.55 0.14 (9.93%)
  5. [verwijderd] 13 juni 2006 14:18

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    rac69 schreef:

    [quote=Rieltijm]
    Bijna gelijkertijd rac, beter 2x dan niet.....

    Ries
    [/quote]

    zekers.koers reageert ook meteen.

    Pre-Market (RT-ECN): 1.55 0.14 (9.93%)
    Yep, ziet er inderdaad een stuk gezelliger uit... maar ik kijk wel weer vanavond om 22.00 uur locale tijd (lees: hier), want met Insmed (en het verrotte beursklimaat) weet je het nooit.....
    Sterkte
    Ries
  6. [verwijderd] 13 juni 2006 14:21

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    MADW (of een ander): post dit ff op Yahoo TRCA-forum, heb daar (gelukkig) geen account, volgens mij staat het er nog niet....
    grinnek... sub 4 vandaag, wel zeker...!
    Richard
  7. [verwijderd] 13 juni 2006 14:22

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Insmed gaat inderdaad de kosten verhalen op Tercica!!!

    Insmed previously notified Tercica that Insmed would seek fees and costs related to Tercica's baseless lawsuit. Given the Court's ruling, Insmed will pursue this option.

    Gr. Gismo
  8. [verwijderd] 13 juni 2006 14:24

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Insmed previously notified Tercica that Insmed would seek fees and costs related to Tercica's baseless lawsuit. Given the Court's ruling, Insmed will pursue this option

    Betalen die hap
    Tecica vandaag onder de 3,50
  10. [verwijderd] 13 juni 2006 14:31

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Rieltijm schreef:

    MADW (of een ander): post dit ff op Yahoo TRCA-forum, heb daar (gelukkig) geen account, volgens mij staat het er nog niet....
    grinnek... sub 4 vandaag, wel zeker...!
    Richard
    Never mind, is al opgepikt door een Insmed aanhanger.....
  14. [verwijderd] 13 juni 2006 14:35

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Een op meerdere fronten mooie dag vandaag!!
    Het zou zo maar eens kunnen, dat de IB-ers vandaag het tapijt onder TRCA uittrekken en instappen in Insmed.
    Het feit, dat ze dan hun geld kwijt zijn, heet in bedrijfstermen: sunk cost.
    En ja, you win some, you lose some!

    Dus nu: Lazard achterna met hun $4.

    Psycho
    gaat diep in de wijnkelder een bijzonder flesje uitzoeken om het te vieren
  15. [verwijderd] 13 juni 2006 14:36

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Eindelijk jongens, eindelijk worden we beloond met goed nieuws. En dan over 11 handelsdagen nog de update eroverheen. Groene ik zou heel snel terug gaan kopen.
  16. [verwijderd] 13 juni 2006 14:36

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Striker_ schreef:

    ja wie liegt er nou?
    trca zei dat ze het verkeerd hadden ingediend?
    Insmed heeft de beste advocaten, dus welk persbericht zou het meest adequate zijn??

    P.
  17. Mark__ 13 juni 2006 14:40

    • Mark__

      Lid sinds: 13 feb 2006

      Laatste bezoek: 17 aug 2023

    • Aanbevelingen

      Ontvangen: 24

      Gegeven: 12

    •    Aantal posts: 1.299

    zoals ik het zie is de case niet dismissed, alleen verschoven naar een andere rechtbank. Dit ivm het rechtsgebied.
  18. Striker_ 13 juni 2006 14:41

    • Striker_

      Lid sinds: 09 mrt 2004

      Laatste bezoek: 05 feb 2025

    • Aanbevelingen

      Ontvangen: 45

      Gegeven: 15

    •    Aantal posts: 2.834

    hoezo de beste advocaten?
    Denken jullie dat TRCA voorliegt in de SEC filings dan???

    Tercica, Inc. today filed a complaint in the U.S. District Court for the Eastern District of Virginia, Richmond division alleging Insmed Incorporated violated the Lanham Act and related statutes relating to false advertising and unfair competition. This action was taken after the presiding Judge for the U.S. District Court for the Northern District of California, the Honorable Saundra Brown Armstrong, dismissed on June 9, 2006 Tercica's complaint for the same violations on the basis that she could not exercise jurisdiction over Insmed, which is based in Virginia. Her ruling also indicated that the complaint should establish that the requisite false statements were disseminated to consumers of Increlex™, e.g., the physicians who purchase and prescribe Increlex, rather than solely to investors. Tercica's re-filing adds new allegations of false and misleading advertising that Insmed disseminated specifically to pediatric endocrinologists, who for purposes of the Lanham Act and related statutes are among the relevant community of consumers affected.

    Of denken jullie soms ook dat ze het niet nog een keer indienen?
    Wat heeft TRCA te verliezen?? juist, NIETS. Alleen nog wat meer geld van hun investeerders.
  19. [verwijderd] 13 juni 2006 14:41

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    08:32 $ 1.55 1,000
    08:32 $ 1.55 1,000
    08:26 $ 1.55 800
    08:16 $ 1.57 2,500
    08:16 $ 1.57 1,500
    08:16 $ 1.57 2,500
    08:16 $ 1.57 1,500
    08:13 $ 1.55 100
    08:13 $ 1.55 900
    08:13 $ 1.55 1,000
    08:13 $ 1.55 100
    08:13 $ 1.55 900
    08:13 $ 1.55 1,000
    08:12 $ 1.55 1,000
    08:12 $ 1.55 1,000


20.047 Posts
Pagina: «« 1 ... 845 846 847 848 849 ... 1003 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.001
AB InBev 2 5.481
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.198
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.517
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.647
Aedifica 3 901
Aegon 3.258 322.651
AFC Ajax 538 7.086
Affimed NV 2 6.287
ageas 5.844 109.885
Agfa-Gevaert 14 2.048
Ahold 3.538 74.292
Air France - KLM 1.025 34.995
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.323
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.812
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.835 242.717
AMG 971 133.054
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 483
Antonov 22.632 153.605
Aperam 92 14.918
Apollo Alternative Assets 1 17
Apple 5 380
Arcadis 252 8.731
Arcelor Mittal 2.033 320.571
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.715
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.078
ASML 1.766 105.993
ASR Nederland 21 4.451
ATAI Life Sciences 1 7
Atenor Group 1 469
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.610
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.390